We've merged with Palleos Healthcare to form a wide-reaching European CRO.
Find out more
ESMO Тargeted Anticancer Therapies Congress 2023 is a great platform for networking with colleagues, interacting with key opinion leaders, asking questions and debating on burning topics in the field of medical oncology, with a particular emphasis on those in early phase clinical development.
OCT Clinical will be represented at the event by Anna Yanaeva, Head of Development Manager. Book a meeting with OCT team to discuss your clinical trial options for your oncology study at ayanaeva@oct-clinicaltrials.com.
OCT Clinical is now operating under Palleos Healthcare brand name.
“The merger will undoubtedly create significant synergies, not just doubling but squaring the expertise of both companies”, Philip Räth, Ph.D., managing director at Palleos, said in the release.
“OCT Clinical is proud to join forces with palleos healthcare, as it has an excellent reputation in the industry it serves. Now we can offer tailored solutions to our clients to meet their diverse clinical research needs and accelerate the time of bringing their products to market”, Dmitry Sharov, CEO at OCT Clinical.